Hájek R, Sevcík P, Ondrásek J, Mayer J, Vásová I, Král Z, Tomíska M, Krahulcová E, Penka M, Kubesová H
II. interní klinika FN, Brno-Bohunice.
Vnitr Lek. 1995 Jan;41(1):21-7.
Maintenance of satisfactory and safe venous access in cancer patients is part of a comprehensive care of cancer patients. As the Hickman/Broviac catheter is today used an implantable port. This port is placed in a subcutaneous pocket. The catheter connected to the port leads into the central vein, usually through the subclavian vein. An application of drugs in the port is done trough the skin. In this time could be used different types of ports, one or two chambers port, low profil port, peripheral port and others. In this paper we reported our two-years experience with 33 totally implantable access systems, which has been implanted in patients with cancer in Masaryk University Hospital Brno Bohunice. In our department was most frequently used port the nonmetallic port IMPLANTOFIX (BRAUN MELSUNGEN). All ports were in place for a total of 5,582 days, in average of 169 days. A frequency of complications were 2.15 on 1,000 days. Four ports were in place for longer than 1 year. A comparison of the incidence of complications in the present study with an analysis of 23 studies reported in literature was satisfactory. Minimal maintenance care, no restriction of life activity, improving quality of life and probably less frequency of infection complications, identify it as a significant advantage for the satisfactory maintenance of venous access of oncology patients in comparison with Hickman/Broviac catheter. Both the patients and the nursing staff showed a very high degree of satisfaction with this system. In cancer patients, especially with poor venous access, and prognosis longer than 6 months can be indicated this system with the advantage for patients.
维持癌症患者满意且安全的静脉通路是癌症患者综合护理的一部分。如今，希克曼/布罗维阿克导管被用作植入式端口。该端口置于皮下袋中。连接到端口的导管通常经锁骨下静脉进入中心静脉。通过皮肤在端口给药。此时可使用不同类型的端口，如单腔或双腔端口、低轮廓端口、外周端口等。本文报告了我们在布尔诺博胡尼采的马萨里克大学医院为癌症患者植入33个完全植入式通路系统的两年经验。在我们科室最常使用的端口是非金属端口IMPLANTOFIX（贝朗医疗）。所有端口总共放置了5582天，平均169天。并发症发生率为每1000天2.15次。有4个端口放置时间超过1年。将本研究中的并发症发生率与文献报道的23项研究分析结果进行比较，结果令人满意。最少的维护护理、不限制生活活动、提高生活质量以及可能较低的感染并发症发生率，表明与希克曼/布罗维阿克导管相比，它是肿瘤患者维持满意静脉通路的一个显著优势。患者和护理人员对该系统都表现出非常高的满意度。对于癌症患者，尤其是静脉通路不佳且预后超过6个月的患者，可推荐使用该系统，它对患者具有优势。
